Gemcitabine HCl

Catalog No.S1149 Batch:S114912

Print

Technical Data

Formula

C9H11F2N3O4.HCI
Molecular Weight 299.66 CAS No. 122111-03-9
Solubility (25°C)* In vitro Water 30 mg/mL (100.11 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
Saline
47.5mg/ml Taking the 1 mL working solution as an example, add 47.5 mg of product into 1 mL of saline and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.
Targets
DNA synthesis (Capan2 cells) [1] DNA synthesis (BxPC3 cells) [1] DNA synthesis (MIAPaCa2 cells) [1] DNA synthesis (PANC1 cells) [1]
12 nM 18 nM 40 nM 50 nM
In vitro Gemcitabine induced NF-κB activity in BxPC-3, PANC-1, and MIA PaCa-2 cells and decreased the level of the NF-κB inhibitor IκBα in BxPC-3 and PANC-1 cells. Treatment of BxPC-3 cells with low dose Gemcitabine for 48 hours results in a dose-dependent increase in NF-κB binding. In contrast, NF-κB DNA binding is decreased in BxPC-3 cells treated with the higher Gemcitabine doses for 48 h; however, 24-h treatment with these higher doses increases NF-κB binding in BxPC-3 cells [2]
In vivo Intratumoral NF-κB activity is significantly elevated (1.3- to 1.8-fold) in the Gemcitabine-treated mice compared to the PBS-treated mice, suggesting that Gemcitabine also induces NF-κB activation. [2]
Features Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

Protocol (from reference)

Cell Assay:[2]
  • Cell lines

    BxPC-3, MIA PaCa-2, and PANC-1 cells

  • Concentrations

    0.2 μM

  • Incubation Time

    24 hours or 48 hours

  • Method

    BxPC-3, MIA PaCa-2, and PANC-1 cells are seeded in a 96-well plate. After 24 hours, cells are treated with vehicle, DMAPT and/or Gemcitabine for an additional 24 hours or 48 hours. Apoptosis is quantified using the Cell Death Detection ELISA to detect the amount of cytoplasmic histone-associated DNA fragments and expressed relative to vehicle-treated cells.
Animal Study:[2]
  • Animal Models

    Athymic nude mice with MIA PaCa-2 cells

  • Dosages

    50 mg/kg or 100 mg/kg

  • Administration

    Administered via i.p.

Customer Product Validation

Data from [Data independently produced by Nucleic Acids Res, 2014, 42(10), 6436-47]

Data from [Cancer Immunol Immunother, 2013, 62, 383–391]

Data independently produced by , , Dr. Helen Sadik of Johns Hopkins University

Data from [Data independently produced by , , Br J Cancer, 2017, 116(3):324-334]

Selleck's Gemcitabine HCl has been cited by 181 publications

UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT [ Int J Biol Sci, 2024, 20(4):1389-1409] PubMed: 38385072
A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer [ Phytomedicine, 2024, 155377] PubMed: none
Establishment, characterization, and biobanking of 36 pancreatic cancer organoids: prediction of metastasis in resectable pancreatic cancer [ Cell Oncol (Dordr), 2024, 10.1007/s13402-024-00939-5] PubMed: 38619751
Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells [ Int J Mol Sci, 2024, 25(6)3211] PubMed: 38542184
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma [ Neoplasia, 2024, 47:100951] PubMed: 38039923
Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer [ Drug Resist Updat, 2023, 71:101005] PubMed: 37647746
Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation [ Nat Cell Biol, 2023, 25(2):309-322] PubMed: 36646789
Analysis and modeling of cancer drug responses using cell cycle phase-specific rate effects [ Nat Commun, 2023, 14(1):3450] PubMed: 37301933
A living ex vivo platform for functional, personalized brain cancer diagnosis [ Cell Rep Med, 2023, S2666-3791(23)00156-8] PubMed: 37192626
Quantifying heterogeneity to drug response in cancer-stroma kinetics [ Proc Natl Acad Sci U S A, 2023, 120(11):e2122352120] PubMed: 36897966

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.